Copertina

Evaluating Local Doses for Prostate Cancer Treatment Using Low‐Dose‐Rate Brachytherapy Considering Oncological Control and Toxicity

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Yasushi Nakai, Kenta Onishi, Isao Asakawa, Makito Miyake, Kaori Yamaki, Fumiaki Isohashi, Akihiko Yoshizawa, Kiyohide Fujimoto, Nobumichi Tanaka
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	The Prostate
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Testosterone Recovery and Quality of Life of Japanese Patients After Short‐Term Neoadjuvant Androgen Deprivation Therapy With Low‐Dose‐Rate Brachytherapy for Prostate Cancer
di: Kenta Onishi, et al.
Pubblicazione: (2025)

Comparison of Prognosis and Health‐Related Quality of Life Between Robot‐Assisted Radical Prostatectomy Versus High‐Dose‐Rate Brachytherapy Combined With External Beam Radiation Therapy and Hormone Therapy for High‐Risk Prostate Cancer
di: Yuya Iwahashi, et al.
Pubblicazione: (2024)

Dose modification in enzalutamide and abiraterone plus prednisolone for castration‐resistant prostate cancer: A subanalysis from the ENABLE study for PCa
di: Nobumichi Tanaka, et al.
Pubblicazione: (2024)

Impact of androgen deprivation therapy on sexual health in patients who underwent brachytherapy for prostate cancer
di: Kenta Onishi, et al.
Pubblicazione: (2025)

Post Hoc Subgroup Analysis of Clinical Outcomes in Patients With High‐Risk Metastatic Hormone‐Naïve Prostate Cancer: Results From a 3‐Year Interim Analysis of the J‐ROCK Study
di: Atsushi Mizokami, et al.
Pubblicazione: (2026)

Efficacy, Safety, and Cost‐Effectiveness of Reduced versus Full Initial Doses of Androgen Receptor Signaling Inhibitors in Non‐Metastatic Castration‐Resistant Prostate Cancer: A Multicenter Retrospective Study
di: Himawari Asanuma, et al.
Pubblicazione: (2026)

Enhancing Diagnostic Accuracy in Prostate Oncology: A Multidimensional Perspective on Prostate Specific Antigen Density
di: Shengyi Chen, et al.
Pubblicazione: (2025)

Mechanical‐Inflammatory Protection: Explaining Favorable Oncological Outcomes in Large Prostates
di: Yu‐Hsiang Lin, et al.
Pubblicazione: (2025)

Impact of Testosterone Recovery on Oncologic Outcomes in High‐Risk, Localized Prostate Cancer
di: Trevor C. Hunt, et al.
Pubblicazione: (2025)

Perioperative Safety and Early Oncologic Outcomes of Salvage Irreversible Electroporation for Radiorecurrent Prostate Cancer
di: Jarrett Noakes, et al.
Pubblicazione: (2026)

Impact of Intraprostatic Simultaneous Integrated Boost on Long‐Term Outcomes in Unfavorable Intermediate‐Risk Prostate Cancer Treated With Dose‐Escalated Radiotherapy and Short‐Term Androgen Deprivation Therapy
di: Cem Onal, et al.
Pubblicazione: (2026)

Long‐Term Oncological Outcomes of Robot‐Assisted Radical Prostatectomy for Clinically Localized Grade Groups 4 and 5 Prostate Cancers Diagnosed on Prostate Biopsy
di: Victor Sandoval, et al.
Pubblicazione: (2025)

Towards Precision Oncology: A New Predictive Machine Learning Model for Early Progression to Castration Resistant Prostate Cancer
di: Miguel Ángel Gómez‐Luque, et al.
Pubblicazione: (2025)

Prognostic Impact of Initial Prostate Specific Antigen Half‐Life After Abiraterone Acetate in High‐Volume Metastatic Hormone‐Sensitive Prostate Cancer: Who May Need Triplet Therapy?
di: Kotaro Suzuki, et al.
Pubblicazione: (2026)

Impact of Pelvic Lymph Node Dissection on Early Oncological Outcomes in Intermediate‐Risk Prostate Cancer Patients With Node‐Negative PSMA PET
di: Baris Esen, et al.
Pubblicazione: (2025)

Prostate Specific Antigen Density and Clinically‐Significant Prostate Cancer: The Influence of Prostatic Volume
di: Elizabeth Robinson, et al.
Pubblicazione: (2025)

The Prognostic Significance of Radiographic Progression Without PSA Progression in Patients With Metastatic Hormone‐Sensitive Prostate Cancer Treated With First‐Line ARPI Therapy
di: Takeshi Tsutsumi, et al.
Pubblicazione: (2026)

A Two‐Factor Bedside Prognostic Score Integrating Eastern Cooperative Oncology Group (ECOG) Performance Status and Aggressive Metastatic Burden in Metastatic Hormone‐Sensitive Prostate Cancer
di: Koichiro Kurokawa, et al.
Pubblicazione: (2026)

Efficacy and Feasibility of Cabazitaxel for Very Elderly Patients of ≥ 80 Years of Age With Metastatic Castration‐Resistant Prostate Cancer: A Real‐World Multi‐Intuitional Analysis
di: Kotaro Suzuki, et al.
Pubblicazione: (2025)

Evaluation of Loss of the Y Chromosome in Peripheral Blood as a Biomarker for Prostate Cancer
di: Jun Lu, et al.
Pubblicazione: (2026)

Safety and Efficacy of Bipolar Transurethral Vaporization of the Prostate and Bipolar Transurethral Resection of the Prostate in the Management of Large Volume Benign Prostatic Hyperplasia: A Prospective Randomized Study
di: Amr M. Lotfy, et al.
Pubblicazione: (2026)

Immunohistochemical Analysis of Androgen Receptor Expression Predicts the Prognosis of Metastatic Castration‐Sensitive Prostate Cancer Patients Receiving Abiraterone Acetate
di: Mitsuhisa Nishimoto, et al.
Pubblicazione: (2025)

The Prognostic Value of the Prostate Adenocarcinoma With Ductal Feature in Patients With Advanced Prostate Cancer Treated With Abiraterone Acetate
di: Yifu Shi, et al.
Pubblicazione: (2025)

Assessment of Circulating Neuroendocrine Tumor Markers at Prostate Cancer Diagnosis: An Investigation of Prostate Cancer With Neuroendocrine Features
di: Tatsuya Shimomura, et al.
Pubblicazione: (2026)

Discovering the Prostate: Notes on History and Historiography
di: Diederik F. Janssen
Pubblicazione: (2025)

Evidence and Rationale for Prostate Cancer Screening
di: Takeshi Takahashi
Pubblicazione: (2025)

Spatial Characteristics of Intraductal Carcinoma of the Prostate
di: Rodolphe Dupuis, et al.
Pubblicazione: (2025)

Impact of Holmium Laser Enucleation of the Prostate on Active Surveillance for Prostate Cancer in Patients With Lower Urinary Tract Symptoms
di: Charly Bâcle, et al.
Pubblicazione: (2025)

Prostatic Surgery With Preservation of the Supramonticular Tissue Versus Standard Surgery for Benign Prostatic Hyperplasia: A Systematic Review
di: Giuston Mendoza‐Chuctaya, et al.
Pubblicazione: (2025)

Impact of the Nadir Androgen Receptor Signaling Inhibitor‐Derived Integrative Response Model in Real‐World Patients With Metastatic Castration‐Sensitive Prostate Cancer
di: Kazuma Yukihiro, et al.
Pubblicazione: (2026)

Safety and Efficacy of Intra‐Prostatic Injection of Betamethasone for Refractory Chronic Nonbacterial Prostatitis: A Prospective Cohort Clinical Study
di: Ahmed Yehia Abdelaziz, et al.
Pubblicazione: (2024)

Prostate‐Specific Antigen Response at Six Months Predicts Progression in Metastatic Hormone‐Sensitive Prostate Cancer Treated With Apalutamide
di: Christian Andrés Martínez Osorio, et al.
Pubblicazione: (2025)

Prostate Extracellular Vesicles and Prognostic Biomarkers of Clinically Significant Prostate Cancer: A Prospective Single‐Institution Pilot Study
di: Cameron J. Britton, et al.
Pubblicazione: (2025)

Mycobacterium Tuberculosis: The Hidden Bacteria in Chronic Prostatitis
di: André Avarese Figueiredo, et al.
Pubblicazione: (2025)

Altered Glycosylation of PSA in Prostate Cancer Tissue
di: Hannu Koistinen, et al.
Pubblicazione: (2025)

Castration Resistance Accelerates Prostate Cancer Kinetics
di: Sheila Jonnatan, et al.
Pubblicazione: (2026)

CHARGE: The “Big Questions” in Prostate Cancer for 2024
di: Andrea K. Miyahira, et al.
Pubblicazione: (2024)

Pathology of a Canine Model of Localized Prostate Carcinoma
di: Nathan K. Hoggard, et al.
Pubblicazione: (2025)

Nectin‐4 Expression in Prostatic Adenocarcinoma: An Immunohistochemical Study
di: Ezra G. Baraban, et al.
Pubblicazione: (2025)

Developments in Ultrasound‐Based Imaging for Prostate Cancer Detection
di: Reid Vassallo, et al.
Pubblicazione: (2025)